Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4641354 | 0.80 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL5573145 | 0.80 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL2949089 | 0.76 | APP (0.51) | LY96ALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL2949086 | 0.76 | APP (0.51) | LY96ALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL4641556 | 0.76 | KDM4E (0.62) | ALDH1A1POLBKMT2A | |
| SCHEMBL4641454 | 0.75 | ALDH1A1 (0.50) | ALDH1A1POLBKMT2A | |
| SCHEMBL6793463 | 0.75 | HPGD (0.48) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL2948511 | 0.74 | ALDH1A1 (0.51) | LY96ALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL2948512 | 0.74 | ALDH1A1 (0.51) | LY96ALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL2951703 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0934924-B1 | NOVEL DIAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | KOWA CO (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-6576642-B2 | Inhibitors of the production of Ig E antibodies, antiallergens | KOWA CO., LTD. (JP) | 2003-06-10 | — | — | US | disclosed |
| US-20010039279-A1 | Diamide compounds and compositions containing the same | KOWA CO., LTD. (JP) | 2001-11-08 | — | — | US | disclosed |
| US-6297283-B1 | EXCELLENT INHIBITORY EFFECT ON THE PRODUCTION OF AN IGE ANTIBODY AND ARE HENCE USEFUL AS ANTIALLERGIC AGENTS | KOWA CO., LTD. (JP) | 2001-10-02 | — | — | US | disclosed |
| EP-0934924-A1 | NOVEL DIAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | KOWA CO. LTD. (JP) | 1999-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039279-A1 | Diamide compounds and compositions containing the same | HRH4, HRH2, HRH1 | LY96 122/4885ALDH1A1 1240/4885POLB 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.